Blueberry Therapeutics Ltd., of Alderley Edge, U.K., completed a £10 million (US$12.7 million) series B fundraising with investment from China Medical Venture Investment Ltd., a wholly owned subsidiary of China Medical System Holdings Ltd., and A&B (HK) Co. Ltd. Blueberry, which develops nano-formulated treatments, will use the net proceeds to fund its development program for BB-2603 for the treatment of onychomycosis and tinea pedis, as well as progressing its earlier-stage acne, topical analgesia and atopic dermatitis programs.